touch ONCOLOGY

Home
touch ONCOLOGY

touchONCOLOGY.com hosts the expert content from peer-reviewed, free-to-access journals – EU Oncology

At touchONCOLOGY, we push the boundaries of online medical education to bring you innovative formats and valuable insights into learning behaviours. Our educational content enhances your ability to provide better patient care and drive positive change in clinical practice. With patients at the heart of everything we do, we aim to help you significantly improve health outcomes. This information is

intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.

25/09/2025

🌟 WCLC 2025: Real-world outcomes in EGFR-mutant NSCLC

A multicentre retrospective study presented at WCLC 2025 examined second-line chemotherapy following first-line targeted therapy in 91 patients with EGFR-mutant advanced NSCLC.

Median progression-free survival was just over five months, median overall survival under a year, and response rates were modest, highlighting the limited durability of standard chemotherapy in this setting.

Dr Igor Gómez-Randulfe notes that these findings provide pragmatic real-world benchmarks and emphasise the ongoing need for more effective post-first-line strategies and personalised treatment approaches.

👉 https://touchoncology.com/insight/wclc-2025-egfr-mutant-nsclc/

25/09/2025

Revisited...

🎯 HER2+ GI cancers: From testing to targeted treatment

Stay ahead in GI oncology with CME-accredited, expert-led guidance from Dr Yelena Janjigian, Prof. Eric Van Cutsem and Prof. Florian Lordick.

In this focused session, you’ll gain:
🔹 Insights on HER2 as a tumour-agnostic biomarker
🔹 Practical tips to optimize HER2 testing
🔹 Key data from HER2-targeted therapy trials
🔹 Strategies to integrate new evidence into patient care

📈 Build confidence in diagnosing and managing HER2+ GI cancers.

📺 Watch now → https://touchoncologyime.org/her2-in-gi-oncology/

This activity is funded by an independent medical education grant from AstraZeneca.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

25/09/2025

🧬 Recognising the Symptoms of Multiple Myeloma

Multiple myeloma is a complex blood cancer that often goes unnoticed in its early stages. In around 70% of patients, the most common symptoms include:

• Persistent or worsening fatigue
• Recurrent infections (pneumonia, sinus, or urinary tract infections)
• Back or bone pain that is persistent or recurring
• Swelling in the arms or legs
• Shortness of breath

If you or someone you know is experiencing any of these signs, consulting a physician promptly can make a real difference. Early diagnosis improves treatment options and outcomes.

💡 Awareness is the first step toward better care.

🔗 Learn more: https://touchoncology.com/speciality/multiple-myeloma/

25/09/2025

🩺 Improving care in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)

How do patient and disease characteristics influence treatment decisions in R/M NPC?

In this CME-accredited activity, Dr Nabil Saba and Dr Victoria Villaflor walk through three real-world cases to highlight:
✔️ Guideline-based treatment strategies
✔️ The role of EBV & PD-L1 status
✔️ When to consider immune checkpoint inhibitors, including for patients with pre-existing autoimmune conditions

💬 “PD-L1 and EBV status, even though we all like to get them, are unlikely to impact treatment choices in the first-line setting.” Dr Nabil Saba

💬 “The benefits of adding a checkpoint inhibitor outweigh the risks in most patients with metastatic nasopharyngeal cancer.” Dr Victoria Villaflor

👉 Gain practical, expert-led insights and earn CME credit: https://touchoncologyime.org/treatment-selection-in-r-m-npc/

This activity is funded by an independent medical education grant from Coherus Biosciences.

This activity is jointly provided by USF Health and touchIME.

American Head and Neck Society - AHNS American Society of Clinical Oncology Community Oncology Alliance

24/09/2025

to touchREVIEWS in Oncology & Haematology. Our journal is a respected platform where your research will be peer-reviewed and accessible internationally, providing practical insights into oncology and haematology.

👉 What We Offer:

• Peer-reviewed, free-to-access publications
• Diverse article types welcomed: reviews, original research and editorials
• Guidance from esteemed editorial board

For more details and to submit your research, visit: https://touchoncology.com/journal-articles/

Share your knowledge, influence clinical practices and enhance patient care in oncology today!

24/09/2025

🔥 UTIs are the second most common infection after respiratory infections, with 50–60% of women experiencing at least one in their lifetime.

They carry a significant public health burden, causing morbidity and costing billions annually across Europe. Urology Week 2025 aims to highlight the prevalence, risk factors, and consequences of UTIs, empowering healthcare professionals to educate patients and improve prevention and management strategies.

Learn more from our expert-led content 👉 https://touchoncology.com/speciality/genitourinary-cancers/

European Association of Urology

24/09/2025

💛 Today, almost 500,000 long-term survivors of childhood cancer live in Europe. To put this in perspective, that’s equal to the population of a major European city such as Antwerp, Lyon, or Lisbon.

This remarkable number reflects progress in care and treatment over the past decades. Yet, survival is only part of the story. Survivors often face long-term physical and emotional effects, and inequalities in access to high-quality care remain a pressing issue across Europe.

We must continue to invest in:
🔹Life-saving research
🔹Faster access to innovative treatments
🔹Equity in survivorship care
🔹Policies that put children and adolescents first

Every survivor represents both hope and a reminder that more must be done.

Explore our content on paediatric oncology:
touchoncology.com/speciality/pediatric-oncology

SIOP Europe, the European Society for Paediatric Oncology - SIOPE

23/09/2025

🌍 Register now for the World Bladder Cancer Patient Coalition Forum 2025!

The World Bladder Cancer Patient Coalition (WBCPC) invites you to join the only global gathering led by and for the bladder cancer patient community, taking place 13–14 October 2025 in Brussels, Belgium.

🗓️ 13 October: Exclusive day for WBCPC member organisations to strengthen global advocacy
🗓️ 14 October: Open to all – patients, carers, healthcare professionals, researchers, and policy stakeholders. Expect:

✅ Clinical and research updates on diagnostics, treatments, and care models
✅ Insights into patient experiences and real-world challenges
✅ Policy and advocacy discussions to shape national and global strategies
✅ Networking opportunities connecting patients and the medical community

Participation is free, with in-person and online access available – making it truly global.

Register here 👉 https://worldbladdercancer.glueup.com/event/149927/register/

23/09/2025

🌟 Exciting news! 🌟

Our Visionary Voices podcast is now on Apple Music! 🎙️

Join us as we explore key trends & innovations in pharma & healthcare.

🎧 Tune in now: https://podcastsconnect.apple.com/my-podcasts/show/visionary-voices

23/09/2025

🌟 WCLC 2025: Trial updates in NSCLC

Final results from the FLAURA2 trial show that adding chemotherapy (platinum–pemetrexed) to first-line osimertinib improves overall survival in EGFR-mutant advanced NSCLC, with median survival near four years.

Experts Drs Igor Gómez-Randulfe and Federico Monaca highlight the importance of shared decision-making to balance survival benefit with potential chemotherapy toxicity.

Read more 👉 https://touchoncology.com/insight/wclc-2025-flaura2-benchmark-nsclc/

International Association for the Study of Lung Cancer

22/09/2025

🌟 Supportive Oncology Spotlight: Integrating Science and Empathy

Dr Celia Díez de los Ríos de la Serna, Multinational Association of Supportive Care in Cancer - MASCC 2025 President Training Fellowship recipient, shares her perspective on the evolving role of supportive care in cancer.

She highlights the importance of:
✅ Combining evidence-based science with compassionate patient care
✅ Multidisciplinary collaboration across oncology, palliative care, nursing, and psychosocial teams
✅ Advancing survivorship research, equitable care access, and workforce wellbeing

“Supportive oncology works best when science and empathy go hand in hand,” says Dr Díez de los Ríos.

Read the full interview 👉 https://touchoncology.com/insight/supportive-oncology-dr-diez-de-los-rios/

22/09/2025

🌍 Advocacy in Action: A Global Call to Address Liver Cancer

“Liver cancer is preventable, yet rising – and patients are too often left out of the prevention and care narrative.” – Sarah Manes, Liver Cancers Program Director, Global Liver Institute

Two recent milestones underscore the urgent need for global action:
🔹 The Lancet Liver Cancer Commission warns that without intervention, hepatocellular carcinoma cases could double by 2050.
🔹 A JCO Global Oncology study highlights the lived experiences of patients and caregivers, calling for better communication, culturally competent care and patient-centred support.

At GLI, data and patient voices come together to drive solutions – because the time to act is now.

📖 Read more: https://touchoncology.com/insight/advocacy-in-action-a-global-call-to-address-liver-cancer/

Address

Website

https://linktr.ee/touchoncology

Alerts

Be the first to know and let us send you an email when touch ONCOLOGY posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to touch ONCOLOGY:

Shortcuts

Want your business to be the top-listed Media Company?

Country:

City:

Our Story

The information posted on this channel is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis or treatment recommendations.

touchONCOLOGY.com is an independent source of peer-reviewed content from our biannual journals – European Oncology & Haematology and Oncology & Hematology Review (US). Free to access, it is designed to support busy physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity. Concise and balanced articles authored by leading voices, are complemented by carefully curated video and podcasts.